ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Therapy, alternative"

  • Abstract Number: 0909 • ACR Convergence 2022

    Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera1, Tomás Cerdó2, Maria Luque-Tevar3, Pilar Font1, Montserrat Romero-Gomez2, Desiree Ruiz-Vilchez4, Sara Remuzgo-Martinez5, Raquel Lopez Mejias6, María Carmen Ábalos-Aguilera7, Rafaela Ortega-Castro1, José Perez-Venegas8, Mª Dolores Ruiz-Montesinos8, Carmen Dominguez8, Carlos Rodriguez-Escalera9, Carmen Romero-Barco9, Antonio Fernandez-Nebro10, Natalia Mena Vazquez10, Jose Luis Marenco11, Julia Uceda Montañez11, Charo Santos12, Nuria Barbarroja1, Mª Angeles Aguirre13, Alejandro Escudero-Contreras2, Eduardo Collantes1, Miguel Ángel González-Gay14 and Carlos Pérez-Sánchez1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3IMIBIC, Córdoba, Spain, 4Reina Sofia University Hospital, Cordoba, Cordoba, Spain, 5Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6IDIVAL, Santander, Spain, 7Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 8Virgen Macarena University Hospital, Sevilla, Spain, 9Virgen de la Victoria Hospital, Málaga, Spain, 10Regional University Hospital of Málaga, Málaga, Spain, 11Virgen de Valme University Hospital, Sevilla, Spain, 12Virgen de Valme University Hospital, Málaga, Spain, 13Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 14Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
  • Abstract Number: 1061 • ACR Convergence 2022

    Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up

    andrea cere, Emanuele Gotelli, Lercara Adriano, Carmen Pizzorni, sabrina Paolino, Alessandri Elisa, Maurizio Cutolo and Alberto Sulli, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: Recent studies proved that aminaphtone is an effective treatment for Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc). Laser Speckle Contrast Analysis (LASCA) further…
  • Abstract Number: 1074 • ACR Convergence 2022

    Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis

    Berengere Molina1, Maria Letizia Urban2, Roberto Padoan3, Pavel Novikov4, Camille Taillé5, Marco Caminati6, Christine Christides7, nicolas schleinitz8, Laura Moi9, Vincent Cottin10, bertrand godeau11, Laurence Bouillet12, Paolo Fraticelli13, Ann Knight14, Jan Walter Schroeder15, Sylvain Marchand-Adam16, Helder Gil17, Elena Gelain18, Giacomo Emmi2 and Benjamin Terrier19, 1Department of Internal Medicine, Cochin Hospital, Paris, France, 2Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 3University of Padova, Padova, Italy, 4Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, 5Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, 6Verona University Hospital, University of Verona, Verona, Italy, 7Avignon hospital, Avignon, France, 8Aix Marseille university, AP-HM, Marseille, France, 9Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, 10Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 11Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, 12Grenoble University Hospital, Grenoble, France, 13Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, 14Akademiska sjukhuset, Uppsala, Sweden, 15ASST GOM Niguarda, Milano, Italy, 16Tours University Hospital, Tours, France, 17Besancon University Hospital, Besançon, France, 18Meyer Children’s University Hospital of Firenze, Florence, Italy, 19National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
  • Abstract Number: 1079 • ACR Convergence 2022

    Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital

    Fabricio Benavides Villanueva1, Cristina Corrales1, Vanesa Calvo Río2, Javier Loricera3, Nuria Aviles4, Juan M Blanco Madrigal5, Santos Castañeda6, Miguel Angel Gonzalez Gay7 and Ricardo Blanco3, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Valdecilla Hospital, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Perpetuo Socorro, Albacete, Spain, 5Basurto University Hospital, Bilbao, Spain, 6Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 7Hospital Universitario Marques de Valdecilla, Lugo, Spain

    Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
  • Abstract Number: 1107 • ACR Convergence 2022

    Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study

    Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China

    Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
  • Abstract Number: 1375 • ACR Convergence 2022

    Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis

    zhaoling wang1, meiping lu2 and qi zheng1, 1Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 2Children’s Hospital of Zhejiang University Medical School, Zhejiang, China

    Background/Purpose: To evaluate the short-term efficacy and safety of baricitinib in children withrefractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. Methods: A monocentric…
  • Abstract Number: 1723 • ACR Convergence 2022

    CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model

    Annegret Van der Aa1, Simon Tessier1, Jean-Philippe Herbeuval2 and Joël Crouzet1, 1Ermium Therapeutics SAS, Paris, France, 2CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…
  • Abstract Number: 1890 • ACR Convergence 2022

    The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study

    Sumapa Chaiamnuay1, Komchan Utamawatin2, Ong-art Phruetthiphat2 and Rit Apinyankul3, 1Phramongkutklao hospital, Nonthaburi, Thailand, 2Phramongkutklao Hospital, Bangkok, Thailand, 3Konkaen University Hospital, Konkaen, Thailand

    Background/Purpose: Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage…
  • Abstract Number: 2014 • ACR Convergence 2022

    Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up

    Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina

    Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
  • Abstract Number: 0025 • ACR Convergence 2022

    Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells

    Eloi Franco-Trepat1, Ana Alonso Pérez1, María Guillán-Fresco2, Miriam López Fagúndez1, Andrés Pazos-Pérez3, Antia Crespo Golmar4, María Piñeiro-Ramil5, Ana Lois Iglesias6, Alberto Jorge-Mora1 and Rodolfo Gomez1, 1MSP Group - Institute IDIS - CHUS - SERGAS, Santiago de Compostela, Spain, 2MSP Group - Institute IDIS - CHUS - SERGAS, Catoira, Spain, 3MSP Group - Institute IDIS - CHUS - SERGAS, Pontevedra, Spain, 4MSP Group - Institute IDIS - CHUS - SERGAS, León, Spain, 5MSP Group - Institute IDIS - CHUAC - SERGA, A Coruña, Spain, 6MSP Group - Institute IDIS - CHUAC - SERGAS, A Coruña, Spain

    Background/Purpose: The progressive degradation of osteoarthritis (OA) cartilage has been associated with articular innate immune responses (IIR) mediated by the Toll-like receptor 4 (TLR4). Additionally,…
  • Abstract Number: 2150 • ACR Convergence 2022

    Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

    Federica Lumetti1, Alarico Ariani2, Camilla Coccolini3, Carlo Salvarani4 and Gilda Sandri4, 1Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, 2Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, 3Università di Modena e Reggio Emilia, Modena, Italy, 4Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy

    Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
  • Abstract Number: 0536 • ACR Convergence 2021

    The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice

    Gonzalo Gómez-Hernández1, Nieves Varela1, Harini Bagavant2, Guillermo Barturen1, Marta E. Alarcon-Riquelme1 and Maria Morell1, 1GENYO.Center for Genomics and Oncological Research, Granada, Spain, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…
  • Abstract Number: 0694 • ACR Convergence 2021

    Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis

    Mari Kamiya1, Fumitaka Mizoguchi1, Hirokazu Sasaki2, Natsuka Umezawa1 and Shinsuke Yasuda3, 1Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 2Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 3Tokyo Medical and Dental University (TMDU), Tokyo, Japan

    Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…
  • Abstract Number: 0733 • ACR Convergence 2021

    A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain

    Emmanuel Maheu1, Sandrine Soriot-Thomas2, Eric Noël3, Hervé Ganry4, Eric Lespessailles5 and Bernard Cortet6, 1Saint-Antoine Hospital, Paris, France, 2CHU Amiens Picardie, Amiens, France, 3Santy Orthopaedic Center, Lyon, France, 4Hergan Consulting 4U, Amiens, France, 5CH Orléans, ORLEANS, France, 6CHU Lille, Lille, France

    Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…
  • Abstract Number: 0738 • ACR Convergence 2021

    Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis

    Weiheng Chen1, Mengge Song1, Yan Jia1, Jigao Sun1, Yan Zhao2, Zhipeng Xue3, Qianglong Chen2, xiangrong Zeng2 and Chenchen Wang4, 1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), 22Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), 31The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), 4Tufts Medical Center, Boston, MA

    Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology